FDA approves new type of schizophrenia drug
The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, ...
New schizophrenia drug gets FDA approval, taking novel approach to treating brain disorder
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...
Boise State Public Radio10h
A new kind of drug for schizophrenia promises fewer side effects
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
New schizophrenia drug could 'change the lives of millions of people'
British scientists have hailed the US approval of a new drug for schizophrenia, saying it “has the potential to change the ...
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
Key Takeaways Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The ...
Business Wire9h
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of ...
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
FDA Approves New Schizophrenia Drug in 70-Year First
The treatment offers hope to thousands of patients who do not respond to existing medications, and has shown promise in treating other neurological disorders.
PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...
Everyday Health12h
FDA Approves the First New Type of Schizophrenia Drug in Decades
Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...
MM&M15h
Bristol Myers Squibb wins FDA approval for first new schizophrenia drug in 30 years
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
THE WEEK4d
The 'game-changing' treatment for schizophrenia
The US Food and Drug Administration (FDA ... About one in 300 people worldwide are affected by schizophrenia, but for decades treatment options have been both static and limited.